WALTHAM, Massachusetts - 18 juill. 2023 (GLOBE NEWSWIRE) -- BVI, l'une des entreprises de chirurgie ophtalmique à la croissance la plus rapide au monde, est fière d'annoncer l'ouverture de sa nouvelle installation ultramoderne à Liège, en Belgique. Celle-ci permettra d’augmenter considérablement sa capacité de production de lentilles intraoculaires (LIO), ouvrant de nouvelles opportunités de croissance et renforçant le leadership environnemental, social et de gouvernance (ESG) de l'entreprise En savoir plus
EvènementsEn savoir plus
- FINEVISION HP is the first patented diffractive trifocal IOL and is one of the flagship products in BVI’s IOL portfolio; FINE Trifocal technology is utilized across the company’s entire range of presbyopia-correcting IOLs.
- The Japan launch follows two key FINEVISION HP 2023 milestones: One million FINEVISION IOL implants sold worldwide and the recent completion of the FINEVISION HP IDE clinical study patient enrollment in the US.
- BVI expects to introduce several IOL models over the next few years in Japan, demonstrating BVI’s commitment to ophthalmic surgeons and their patients in Japan.
WALTHAM, Mass.,June 19th, 2023 (GLOBE NEWSWIRE) BVI, one of the fastest growing surgical ophthalmic businesses in the world, is thrilled to announce the official launch of FINEVISION HP in Japan. The FINEVISION HP hydrophobic and glistening free trifocal IOL represents a significant breakthrough in trifocal technology as the first trifocal platform to offer cataract patients high quality vision across all distances. En savoir plus
WALTHAM, MA - May 1, 2023 (GLOBE NEWSWIRE) — BVI, a diversified global ophthalmic device company, today announced it has completed enrollment of its U.S. Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal intraocular lens, FINEVISION® HP. En savoir plus
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) — BVI, a diversified global ophthalmic device company, today announced certification for its intraocular lens (IOL) portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medical Device Directive (MDD). En savoir plus
Government customers can now purchase BVI’s high-quality ophthalmic products through Lovell Government Services’ ECAT Contract. En savoir plus